PITCH GLOBAL in SAN DIEGO on June 22 June 08, 2026 | By Ross Youngs Ross Youngs, CEO of Biosortia, will be at BIO in San Diego all week and will be presenting at Pitch Global. Let’s discuss how our Grounded Exclusive Biological DATA supercharges Biosortia’s discovery engine. Ask anyone — It’s about the DATA. What can Biosortia’s 13-stage AI
Moderna and other groups get $60 million to develop Ebola vaccine (June 1, 2026) by By Jennifer Rigby, Mariam E Sunny and Julie Steenhuysen Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting their money behind more mature and de-risked assets. June 1 (Reuters) – Global health organisation CEPI will
By Biosortia Microbiomics, May 28, 2026 Biosortia: Reversing the Antibiotic Apocalypse—A Global Call to Action WATCH NOW 1. The Existential Threat: Chronic Infections and the Silent Biofilm Catastrophe The world stands on the brink of a medical crisis in which common infections are becoming untreatable. This silent catastrophe is driven by the “Biofilm Barrier”—a sophisticated, multicellular, fortress-like architecture that shields
By Ross Youngs, May 28, 2026 Has synthetic chemical screening hit the wall? Traditional pharma libraries often yield hit rates below 0.1% when searching for complex aging targets. It’s a massive needle-in-a-haystack problem that costs millions and takes years. Even then, once de-risked preclinical, it takes 40 programs to get an approval. Microbiome-based starting point, once de-risked, takes only 4.4
